Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.26+0.26 (+8.67%)
Close on Nov 18, 2026Market cap $564.44MP/E –Yield –
Entera Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Entera Bio's operating income for the twelve months ending Jun 30, 2026 was -$14.40M. For fiscal 2025 it was -$11.53M. The highest annual figure on record is -$5.37M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.53M | – |
| FY2024 | Dec 31, 2024 | -$9.59M | – |
| FY2023 | Dec 31, 2023 | -$8.89M | – |
| FY2022 | Dec 31, 2022 | -$13.02M | – |
| FY2021 | Dec 31, 2021 | -$12.22M | – |
| FY2020 | Dec 31, 2020 | -$11.17M | – |
| FY2019 | Dec 31, 2019 | -$11.45M | – |
| FY2018 | Dec 31, 2018 | -$10.86M | – |
| FY2017 | Dec 31, 2017 | -$11.34M | – |
| FY2016 | Dec 31, 2016 | -$5.37M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.67M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.34M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.39M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.21M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.25M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.22M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.03M | – |
See a number that looks wrong?